UK begins trial of latest vaccine candidate for coronavirus

The vaccine uses synthetic strands of genetic code based on the virus.

16 June 2020 | 13:45

Source: Associated Press

  • Source: Associated Press
  • Last update: 16 June 2020 | 13:45

This undated handout photo provided by Imperial College London shows a COVID-19 vaccine candidate. Scientists at Imperial College London will start immunizing people in Britain this week with their experimental coronavirus shot, becoming the latest entry into the race to find an effective vaccine. In a statement on Monday, June 15, 2020 the British government said that 300 healthy people will be immunized with two doses of the COVID-19 vaccine candidate developed at Imperial College London, which has been backed by £41 million pounds ($51 million) in government funding. About a dozen vaccine candidates are in early stages of testing in thousands of people. (AP Photo).

LONDON: Scientists at Imperial College London will start immunizing people in Britain this week with their experimental coronavirus shot, becoming the latest entry into the race to find an effective vaccine to stop the pandemic.

In a statement, the British government said 300 healthy people will be immunized with two doses of the COVID-19 vaccine candidate developed at Imperial, which has been backed by 41 million pounds ($51 million) in government funding.

So far, the vaccine candidate developed by Imperial College London has only been tested in animals and in the laboratory, where it produced much higher levels of antibodies than would normally be seen in infected people.

Many scientists have warned that the pandemic might only be stopped with an effective vaccine, which typically takes years to develop.

“In the long term, a viable vaccine could be vital for protecting the most vulnerable, enabling restrictions to be eased and helping people get back to normal life,” said Robin Shattock, who is leading the vaccine research.

The vaccine uses synthetic strands of genetic code based on the virus. Once injected into the muscle, the body’s own cells are instructed to make copies of a spiky protein on the coronavirus. That should in turn trigger an immune response so the body can fight off any future COVID-19 infection.

Dr. Doug Brown, chief executive of the British Society for Immunology, said the particular technology used by Imperial College London should theoretically lead to long-term immunity against the coronavirus but needs to go through rigorous testing. He was not linked to the trial.

About a dozen vaccine candidates are currently in early stages of testing in thousands of people. There are no guarantees any will work but there’s increasing hope that at least some could be ready by the end of the year.

Oxford University recently began an advanced study involving 10,000 volunteers, and the U.S. is preparing for even larger studies in July that involve 30,000 people each testing different candidates, including Oxford’s and one made by the National Institutes of Health and Moderna Inc.

Scientists have never created vaccines from scratch this fast and it’s far from clear that any will ultimately prove safe and effective. Still, numerous countries, including Britain, France, Germany, the Netherlands and the U.S., have already placed advance orders for millions of vaccines.

Worldwide, there have been 8 million confirmed coronavirus cases and over 437,000 deaths, according to a tally by Johns Hopkins University.

The World Health Organization noted Monday that about 100,000 new infections have been reported every day for the past two weeks and that relaxed lockdown restrictions in many countries have led to a new surge of cases.

Show Comments

An-Nahar is not responsible for the comments that users post below. We kindly ask you to keep this space a clean and respectful forum for discussion.